Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19. A Randomized Clinical Trial
JAMA. Published online February 17, 2021. doi:10.1001/jama.2020.26848
Igor H. Murai, PhD1; Alan L. Fernandes, PhD1; Lucas P. Sales, MSc1; et alAna J. Pinto, BSc2; Karla F. Goessler, PhD2; Camila S. C. Duran, MD1; Carla B. R. Silva, MD1; André S. Franco, MD1; Marina B. Macedo, MD, MSc1; Henrique H. H. Dalmolin, MD1; Janaina Baggio, MD1; Guilherme G. M. Balbi, MD1; Bruna Z. Reis, PhD1; Leila Antonangelo, MD, PhD3; Valeria F. Caparbo, PhD1; Bruno Gualano, PhD2,4; Rosa M. R. Pereira, MD, PhD1
Vitamin D not given until 10 days after symptoms (15 days after infection started?)
- Question What is the effect of a single high dose of vitamin D3 on hospital length of stay among hospitalized patients with moderate to severe coronavirus disease 2019 (COVID-19)?
- Findings In this randomized clinical trial that involved 240 hospitalized patients with moderate to severe COVID-19, a single dose of 200 000 IU of vitamin D3, compared with placebo, did not significantly reduce hospital length of stay (median of 7.0 vs 7.0 days; unadjusted hazard ratio for hospital discharge, 1.07).
- Meaning The study does not support the use of a high dose of vitamin D3 for treatment of moderate to severe COVID-19 in hospitalized patients.
Importance The efficacy of vitamin D3 supplementation in coronavirus disease 2019 (COVID-19) remains unclear.
Objective To investigate the effect of a single high dose of vitamin D3 on hospital length of stay in patients with COVID-19.
Design, Setting, and Participants This was a multicenter, double-blind, randomized, placebo-controlled trial conducted in 2 sites in Sao Paulo, Brazil. The study included 240 hospitalized patients with COVID-19 who were moderately to severely ill at the time of enrollment from June 2, 2020, to August 27, 2020. The final follow-up was on October 7, 2020.
Interventions Patients were randomly assigned to receive a single oral dose of 200 000 IU of vitamin D3 (n = 120) or placebo (n = 120).
Main Outcomes and Measures The primary outcome was length of stay, defined as the time from the date of randomization to hospital discharge. Prespecified secondary outcomes included mortality during hospitalization; the number of patients admitted to the intensive care unit; the number of patients who required mechanical ventilation and the duration of mechanical ventilation; and serum levels of 25-hydroxyvitamin D, total calcium, creatinine, and C-reactive protein.
Results Of 240 randomized patients, 237 were included in the primary analysis (mean [SD] age, 56.2 [14.4] years; 104 [43.9%] women; mean [SD] baseline 25-hydroxyvitamin D level, 20.9 [9.2] ng/mL). Median (interquartile range) length of stay was not significantly different between the vitamin D3 (7.0 [4.0-10.0] days) and placebo groups (7.0 [5.0-13.0] days) (log-rank P = .59; unadjusted hazard ratio for hospital discharge, 1.07 [95% CI, 0.82-1.39]; P = .62). The difference between the vitamin D3 group and the placebo group was not significant for in-hospital mortality (7.6% vs 5.1%; difference, 2.5% [95% CI, –4.1% to 9.2%]; P = .43), admission to the intensive care unit (16.0% vs 21.2%; difference, –5.2% [95% CI, –15.1% to 4.7%]; P = .30), or need for mechanical ventilation (7.6% vs 14.4%; difference, –6.8% [95% CI, –15.1% to 1.2%]; P = .09). Mean serum levels of 25-hydroxyvitamin D significantly increased after a single dose of vitamin D3 vs placebo (44.4 ng/mL vs 19.8 ng/mL; difference, 24.1 ng/mL [95% CI, 19.5-28.7]; P < .001). There were no adverse events, but an episode of vomiting was associated with the intervention.
Conclusions and Relevance Among hospitalized patients with COVID-19, a single high dose of vitamin D3, compared with placebo, did not significantly reduce hospital length of stay. The findings do not support the use of a high dose of vitamin D3 for treatment of moderate to severe COVID-19.
Trial Registration ClinicalTrials.gov Identifier: NCT04449718
Preprint version of this is also on VitaminDWiki ((Severe COVID-19 not fought by vitamin D when given too late - RCT Nov 18, 2020)
- " 208 participants they would have 80% power to detect a 50% difference in hospital length of stay, which is a highly improbable result"
- "most of the patient population would be considered moderately ill and the results cannot be generalized to critically ill patients, who were excluded." Mechanical Ventilation and ICU
- “A recent study demonstrated that buckets of water made no difference in tackling a house fire, therefore we conclude there is no benefit to using water for firefighting”."
- a bucket of water can't put out a raging house fire... (but pretty useful for putting out the cigarette before it catches on the curtains though)
- "There are considerable differences between the control and treatment groups in a number of variables known to be highly relevant to covid severity and hence length of stay. The treatment group had more people with diabetes who are more likely to die from covid."
- - - - - - - -
The following would have been a useful vitamin D level if it had been achieved a week sooner
Note: The founder of VitaminDWiki enclosed 200,000 IU of Vitamin D in his Christmas cards
to be taken immediately if get COVID-19 symptoms Four capsules of 50,000 IU each on a small blister pack Amazon
As of Oct 18, 2021, the page had: 34 trials, 6 trial results, 27 meta-analyses and reviews, 64 observations, 35 recommendations, 55 associations, 89 speculations, 48 videos see related: Governments, HealthProblems, Hospitals, Dark Skins, 26 risk factors are ALL associated with low Vit D, Recent Virus pages Fight COVID-19 with 50K Vit D weekly Vaccines
- COVID-19 treated by Vitamin D (example: ICU reduced by 5X) – 20th meta-analysis Oct 13, 2021
- Severe COVID-19 2.5 X more likely if low vitamin D (23 studies) – 19th meta-analysis Oct 2021
- COVID-19 mortality extrapolates to zero at 50 ng of vitamin D – 18th Meta-analysis Sept 2021
- COVID-19 death 1.6 X more likely if low vitamin D (24 studies) – 17th meta-analysis Aug 2021
- Severe COVID-19 5X more likely if low vitamin D (23 studies) – 16th meta-analysis July 2021
- Severe COVID-19 3.5 more likely if low vitamin D (30 studies) – meta-analysis July 2021
- COVID-19 patients who had supplemented with Vitamin D were 3X less likely to enter ICU – June 2021
- Low Calcium associated with severe COVID-19 – several studies
- COVID-19 mortality 3X more likely if low vitamin D (999,179 people) – meta-analysis March 29, 2021
- COVID-19 was 2.6X more severe if very low Vitamin D (43 studies) – meta-analysis March 26, 2021
- Low Vitamin D associated with 2.7X more severe COVID-19 – 12th MA March 5, 2021
- Vitamin D supplementation fights COVID-19 – 11th meta-analysis Jan 24, 2021
- 3.7 X less likely to die of COVID-19 if supplemented with Vitamin D - meta-analysis Jan 5, 2021
- Less likely to test positive for COVID-19 if higher Vitamin D – meta-analysis Jan 6, 2021
- Vitamin D reduces COVID-19 by 80 percent - anonymous meta-analysis - Jan 5, 2021
- COVID-19 1.7X more likely to be severe if low Vitamin D - meta-analysis Oct 2020
- Low Vitamin D associated 1.8X increased risk of COVID-19 death in hospital – meta-analysis Nov 4, 2020
- Acute viral respiratory infections (RTI) reduced by Vitamin D - 20 reviews - Aug 2020
- Prudent to consider that Vitamin D has a role in COVID-19 – meta-analysis – Aug 7, 2020
- Risk of enveloped virus infection is increased 50 percent if poor Vitamin D Receptor - meta-analysis Dec 2018
- Hepatitis B patients have 2 ng lower level of Vitamin D – meta-analysis June 2019
- Influenza Vaccination not benefited by lowish levels of vitamin D – meta-analysis March 2018
Title change made Sept 2021 caused the visitor count to reset.
There have actually been
Short URL = https://is.gd/04449718
|217 visitors, last modified 18 Sep, 2021,
|16232||Brazil RCT 200K.jpg||admin 18 Sep, 2021 17:25||29.16 Kb||70|
|15061||Four 50K IU.jpg||admin 18 Feb, 2021 01:42||40.41 Kb||488|
|15060||Brazil RCT.jpg||admin 18 Feb, 2021 00:26||20.46 Kb||334|
|15059||Vit D COVID RCT Brazil.pdf||PDF 2021||admin 18 Feb, 2021 00:25||401.00 Kb||103|